News

PHI achieves market acceptance goals

Prior to the company’s IPO in early 2014, three market acceptance goals were set out to be achieved by the end of 2015: 50 units in operation at customers and key opinion leaders, collaboration agreements with 8 key opinion leaders and the company’s main product HoloMonitor® M4 shall be manufactured in series production.
Read More

Big Pharma embraces HoloMonitor technology from PHI

Upon completion of an extensive evaluation in early September one of the top pharmaceutical companies in the world has decided to acquire two Holo­Monitor® instruments. The ordered configuration is an automated version of the HoloMonitor platform.
Read More

HoloMonitor technology help researchers fight ovarian cance

Ovarian cancer is one of the deadliest forms of cancer. Researchers at the Center of Excellence for Holographic Imaging at Northeastern University in Boston have used HoloMonitor technology to study how the immune system can be stimulated to fight this deadly cancer form. The research results have been published in Journal of Clinical & Cellular Immunology.
Read More

Florida International University and PHI collaborate to fight cancer

Florida International University (FIU) and PHI have entered a collaboration agreement. To determine the scope of a long-term collaboration, PHI will initially provide FIU with a HoloMonitor instrument during 4 months. The instrument will be used to characterize breast cancer stem cells. Additional information about the collaboration has been published on the university’s website, breakthroughs.fiu.edu.
Read More

PHI provides second HoloMonitor® to University of California, San Francisco to accelerate skin cancer research

PHI has entered into a collaboration agreement with University of California, San Francisco (UCSF) to accelerate ongoing skin cancer research at UCSF. Under the 11 month agreement, PHI will provide a HoloMonitor® M4.5 with a motorized stage to supplement the instrument which UCSF purchased previously for preclinical research in the field. “A key strategic goal for …
Read More

HoloMonitor technology shows versatility as important tool in nanotechnology research

Researchers at University of Pannonia in Hungary recently published a scientific study where HoloMonitor technology from Phase Holographic Imaging (PHI) is used to study cell growth on nanostructures. The study confirms that HoloMonitor technology has a unique potential to become an important tool for investigating cellular behavior on nanostructures under the influence of pharmaceuticals. In …
Read More

PHI expands into Australia and respiratory research

In April Phase Holographic Imaging (PHI) had outstanding orders of approx­imately 2 MSEK, consisting of 13 HoloMonitor M4 units and 15 orders for the recently launched motorized stage. A portion of these units have now been delivered. Among others, a HoloMonitor M4 with motorized stage has been delivered to one of the leading institutes for …
Read More

Germany’s largest biomedical research institute foster the use of PHI technology

German Cancer Research Center (DKFZ) in Heidelberg and PHI have signed a collaboration agreement, to foster the use of HoloMonitor technology at DKFZ. A HoloMonitor M4 with a motorized XY-stage will be centrally installed at the Imaging and Cytometry Core Facility and made available to the over 1 000 cancer researchers at DKFZ. “DKFZ is one …
Read More

PHI expands collaboration with Karolinska Institutet

Arne Lindqvist and his research group Karolinska Institutet and PHI have entered a second research agreement. Assistant Professor Lindqvist’s research group studies how DNA-damage affects human cell division. To facilitate this research, the group actively develops novel microscopy-based techniques.   PHI will support Professor Lindqvist’s research by providing HoloMonitor instrument, training and support during six …
Read More

Research based on HoloMonitor technology to be present at the annual meeting of the American Association for Cancer Research

Northeastern University scientists, associated with the Holographic Imaging Cytometry Program of Excellence, have been selected to present their research results at three occasions at the annual meeting of the American Association for Cancer Research (AACR) in April 2015. In their research, the scientists have used the HoloMonitor M4 time-lapse cytometer from Phase Holographic Imaging to …
Read More